Atyr Pharma Inc. (ATYR)
NASDAQ:ATYR
Want to see ATYR full AI Analyst Report?
Top Page
aTyr Pharma
(NASDAQ:ATYR)
Select Model
Select Model
Rating:44Neutral
Price Target:
$0.49
▼(-42.47% Downside)
Action:Reiterated
Date:05/16/26
Overall score is weighed down primarily by very weak financial fundamentals (minimal revenue, large losses, and substantial cash burn) and a clear downtrend in technical indicators. A positive Phase 3 trial plan and supportive FDA feedback provide some offset, while valuation is difficult to assess due to negative earnings and no dividend data.
Positive Factors
Regulatory clarity & Phase 3 plan
FDA Type C minutes giving clear endpoint guidance and patient-selection refinements materially reduce regulatory uncertainty for efzofitimod. A well-specified global Phase 3 with revised dosing and monitoring creates a more rigorous path to approval and long-term value realization if successful.
Negative Factors
Negligible revenue and large losses
Minimal revenue and sustained multi-year losses show the company lacks commercial cash flow, making operations fully development-funded. Persistent negative earnings erode equity over time, heightening reliance on external financing which can dilute shareholders and constrain long-term strategic flexibility.
Read all positive and negative factors
Positive Factors
Negative Factors
Regulatory clarity & Phase 3 plan
FDA Type C minutes giving clear endpoint guidance and patient-selection refinements materially reduce regulatory uncertainty for efzofitimod. A well-specified global Phase 3 with revised dosing and monitoring creates a more rigorous path to approval and long-term value realization if successful.
Read all positive factors
aTyr Pharma (ATYR) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$50.94M
Dividend YieldN/A
Average Volume (3M)2.46M
Price to Earnings (P/E)―
Beta (1Y)1.14
Revenue GrowthN/A
EPS Growth8.93%
CountryUS
Employees56
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.73
Shares Outstanding98,051,210
10 Day Avg. Volume5,654,949
30 Day Avg. Volume2,463,534
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)1.08
Price to Sales (P/S)383.25
P/FCF Ratio-1.17
Enterprise Value/Market Cap1.05
Enterprise Value/Revenue282.73
Enterprise Value/Gross Profit-2.41
Enterprise Value/Ebitda-0.76
Forecast
1Y Price Target
$6.38Price Target Upside650.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.59
Revenue Forecast (FY)N/A
aTyr Pharma Business Overview & Revenue Model
Company Description
aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in...
How the Company Makes Money
aTyr Pharma is a clinical-stage biopharmaceutical company and, as such, it does not typically generate recurring revenue from product sales because its candidates have not been commercialized. Its revenue, when present, has historically been expec...
aTyr Pharma Earnings Call Summary
Earnings Call Date:Mar 13, 2025
(Q4-2024)
| % Change Since: |
Next Earnings Date:Aug 12, 2026
Earnings Call Sentiment Positive
The earnings call highlighted significant progress in clinical trials and market opportunities, along with a solid financial position. However, there are challenges related to limited clinical studies for benchmarking and high unmet medical needs in the current market landscape.Positive Updates
Completion of Enrollment in EFZO-FIT Phase 3 Study
aTyr completed enrollment in the global pivotal Phase 3 EFZO-FIT study of efzofitimod in patients with pulmonary sarcoidosis, enrolling 268 patients across 85 centers in 9 countries.
Negative Updates
Limited Clinical Studies in Sarcoidosis
There are limited clinical studies in sarcoidosis to benchmark against, presenting challenges in pioneering a path forward for measuring improvements in this patient population.
Read all updates
Q4-2024 Updates
Positive
Negative
Completion of Enrollment in EFZO-FIT Phase 3 Study
aTyr completed enrollment in the global pivotal Phase 3 EFZO-FIT study of efzofitimod in patients with pulmonary sarcoidosis, enrolling 268 patients across 85 centers in 9 countries.
Read all positive updates
Company Guidance
During aTyr Pharma's fourth quarter and full year 2024 conference call, the company provided comprehensive guidance on their clinical developments and strategic outlook. They highlighted the completion of enrollment in the pivotal Phase 3 EFZO-FIT study for efzofitimod, aimed at treating pulmonary sarcoidosis. This trial involves 268 patients across 85 centers in nine countries, testing doses of 3 mg/kg and 5 mg/kg against a placebo over 52 weeks, with a primary endpoint focused on steroid reduction. The company also noted that 75% of diagnosed sarcoidosis patients are prescribed steroids, with the U.S. patient population being 30% larger than previously estimated. Additionally, they have observed four positive data and safety monitoring board reviews with no safety concerns. Financially, aTyr ended 2024 with $75.1 million in cash, supplemented by $18.8 million from an ATM offering. They project their cash runway will last through a year following the Phase 3 readout. The company also discussed plans for commercial readiness and the potential for efzofitimod in a $2-5 billion ILD market, with sarcoidosis representing a significant portion.aTyr Pharma Financial Statement Overview
Summary
Income Statement
9
Very Negative
Balance Sheet
52
Neutral
Cash Flow
12
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 190.00K | 190.00K | 235.00K | 353.00K | 10.39M | 0.00 |
| Gross Profit | -22.33M | -1.36M | 235.00K | 353.00K | 8.69M | -1.30M |
| EBITDA | -70.95M | -76.07M | -66.37M | -52.18M | -44.71M | -32.47M |
| Net Income | -70.03M | -74.12M | -64.02M | -50.39M | -45.34M | -33.77M |
Balance Sheet | ||||||
| Total Assets | 79.65M | 94.16M | 96.83M | 120.65M | 95.79M | 115.54M |
| Cash, Cash Equivalents and Short-Term Investments | 66.51M | 78.69M | 72.13M | 98.17M | 66.15M | 107.91M |
| Total Debt | 11.70M | 12.03M | 13.28M | 15.10M | 11.53M | 1.38M |
| Total Liabilities | 21.91M | 26.88M | 27.00M | 30.18M | 24.50M | 6.41M |
| Stockholders Equity | 57.93M | 67.48M | 70.02M | 90.66M | 71.46M | 109.30M |
Cash Flow | ||||||
| Free Cash Flow | -59.30M | -62.06M | -69.18M | -37.44M | -43.53M | -33.27M |
| Operating Cash Flow | -59.08M | -61.99M | -69.12M | -33.22M | -41.89M | -33.08M |
| Investing Cash Flow | 10.86M | -5.05M | 17.23M | -20.13M | 47.24M | -91.57M |
| Financing Cash Flow | 47.24M | 66.01M | 39.86M | 66.23M | 5.45M | 110.03M |
aTyr Pharma Technical Analysis
Negative
0.85
Price Trends
0.79
Negative
0.82
Negative
1.47
Negative
Market Momentum
-0.08
Positive
36.11
Neutral
16.17
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ATYR, the sentiment is Negative. The current price of 0.85 is above the 20-day moving average (MA) of 0.75, above the 50-day MA of 0.79, and below the 200-day MA of 1.47, indicating a bearish trend. The MACD of -0.08 indicates Positive momentum. The RSI at 36.11 is Neutral, neither overbought nor oversold. The STOCH value of 16.17 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ATYR.
aTyr Pharma Risk Analysis
aTyr Pharma disclosed 70 risk factors in its most recent earnings report. aTyr Pharma reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
aTyr Pharma Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $273.43M | -6.79 | -118.24% | ― | 138.86% | 42.14% | |
46 Neutral | $197.54M | -7.18 | -59.95% | ― | ― | -24.56% | |
44 Neutral | $50.94M | -1.77 | -99.87% | ― | ― | 8.93% | |
42 Neutral | $81.68M | -7.23 | 102.92% | ― | ― | ― |
* Healthcare Sector Average
ATYR
aTyr Pharma
0.53
-3.22
-85.87%
XBIT
XBiotech
2.39
-0.48
-16.72%
PRLD
Prelude Therapeutics
4.50
3.59
394.51%
CNTX
Context Therapeutics
2.23
1.54
222.72%
OKYO
OKYO Pharma Limited Sponsored ADR
1.60
-0.05
-3.03%
aTyr Pharma Corporate Events
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
aTyr Pharma Announces New Phase 3 Sarcoidosis Trial
Positive
May 11, 2026
On May 11, 2026, aTyr Pharma reported a regulatory and clinical update on efzofitimod in pulmonary sarcoidosis after receiving minutes from a Type C meeting with the U.S. Food and Drug Administration. The agency’s feedback affirmed forced vi...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.